BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26473193)

  • 1. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
    Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
    Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of rhabdomyosarcoma and its molecular basis.
    Parham DM; Barr FG
    Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
    Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
    Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
    Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.